Journal of the Society for Cardiovascular Angiography & Interventions最新文献

Background: The mechanistic association between the hydraulic forces generated during contrast injection and the risk of coronary injury is poorly understood. In this study, we sought to evaluate whether contrast injections increase intracoronary pressures beyond resting levels and estimate the risk of hydraulic propagation of coronary dissections.

Methods: This is a prospective, single-arm, multicenter study that included patients with nonculprit, non-flow-limiting coronaries. A continuous 60-second pressure recording was taken at 5 predetermined locations during contrast injections: distal, mid, and proximal vessel, catheter tip, and inside the catheter. The primary end point was the change in intracoronary peak pressure between resting and injections in each location.

Results: A total of 269 pressure recordings (58 vessels; 52 patients) were analyzed. Injections led to a small increase in peak pressure in the distal (mean difference, +4.5 mm Hg; 95% CI, 1.5-7.4), mid (mean difference, +4.1 mm Hg; 95% CI, 1.4-6.9), and proximal (mean difference, +5.1 mm Hg; 95% CI, 2.5-7.7) vessel locations, and much higher increases at the catheter tip (mean difference, +11.7 mm Hg; 95% CI, 5.8-17.7) and inside the catheter (mean difference, +77.5 mm Hg; 95% CI, 64.5-90.4). Compared to the distal vessel, pressure changes were only significant at the catheter tip (+10 mm Hg; P < .01) and inside the catheter (+79.1 mm Hg; P < .01).

Conclusions: Contrast injections lead to negligible changes in intracoronary pressures beyond the catheter tip. Although it is sensible to minimize injections when coronary dissections are close to the catheter, it is unlikely that they would cause injuries beyond the catheter tip.

Background: Routine preprocedural fasting before cardiac catheterization remains common practice, despite a lack of robust evidence to support this practice. We investigated the impact of a liberal nonfasting strategy vs a standardized nil per os (NPO) regimen prior to cardiac catheterization.

Methods: Adult inpatients undergoing elective or urgent cardiac catheterization were randomized (1:1 ratio) to either NPO past midnight or ad libitum intake of liquids and solids (without dietary constraints) until immediately prior to the procedure. Only patients at high risk of aspiration or undergoing complex interventions were excluded. The primary end point was preprocedural patient-reported well-being scores (scaled 0-5, with 0 signifying absence of ailment and 5 the most extreme form), for variables including hunger, fatigue, anxiety, and nausea. A composite score summed the individual scores for hunger and fatigue. Other end points were periprocedural adverse events including emesis, aspiration, or intubation, in addition to postprocedural satisfaction.

Results: A total of 198 patients (65% male and 42% Black) were included in the final analysis. There were no differences in baseline characteristics between groups. Time from most recent oral intake (liquid or solid) to the start of the procedure averaged 148 minutes for the nonfasting group and 970 minutes for the NPO strategy (P < .001). The composite preprocedural well-being score was significantly better in the nonfasting arm (2.4 ± 2.4 nonfasting vs 6.0 ± 2.5 NPO; P < .001), as were the individual components of hunger (0.9 ± 1.5 vs 3.7 ± 1.5; P < .001), fatigue (1.5 ± 1.6 vs 2.3 ± 1.8; P < .001), and nausea (0.1 ± 0.5 vs 0.5 ±1.2; P = .006). There were no significant differences in adverse events between groups. Overall postprocedural satisfaction scores were significantly better in the nonfasting vs NPO group (0.3 ± 0.7 vs 1.0 ± 1.3, respectively; P < .001).

Conclusions: In this single-center randomized trial, a liberal nonfasting strategy prior to cardiac catheterization significantly improved patient well-being and satisfaction without compromising safety. Given the findings of this and other studies, routine fasting prior to cardiac catheterization should be reconsidered.

Background: Atherosclerotic renal artery stenosis (ARAS) may provoke hypertension and/or impaired kidney function. Some patients develop uncontrolled hypertension and deteriorating kidney function despite optimal medical therapy. In these patients, endovascular treatment is an important therapeutic option. ARTISAN was a prospective, open-label, single-arm, multicenter clinical trial to evaluate the safety and effectiveness of the iCast RX covered stent both functionally for reestablishing renal artery flow, and clinically for controlling resistant hypertension.

Methods: Patients considered for enrollment had average systolic blood pressure (SBP) ≥155 mm Hg despite taking 3 antihypertensive medications. Prior to enrollment and covered stent placement, angiographic confirmation of ARAS ≥80% with physiologic significance was required. Clinical assessments were performed at 30 days, 9 months, and annually through 36 months. Covered stent safety and efficacy were based on 9-month coprimary end points, including primary vessel patency and SBP improvement at 9 months. Secondary outcomes included target lesion revascularization, major adverse events, and secondary patency.

Results: Sixty-eight of the planned 138 subjects were enrolled. Primary patency was seen in 94.3% of subject lesions; the mean SBP reduction was 15.7 mm Hg. The functional and clinical end points met prespecified performance goals of 70% primary patency (P < .0001) and ≥10 mm Hg SBP decrease (P = .0192), respectively, at 9 months. Six subjects (8.8%) experienced 7 major adverse events within 36 months. The clinically driven target lesion revascularization rate was 7.3% at 36 months.

Conclusions: The high primary patency and improvement in SBP, persisting through 36 months, suggest that the iCast RX covered stent is safe and effective for the treatment of appropriately selected patients with ARAS.

Transcatheter aortic valve repair (TAVR) presents a minimally invasive alternative to traditional surgical valve replacement, albeit not without its own set of complications. A rare complication is the infolding of the self-expanding valve, which can precipitate cardiac arrest. The estimated incidence rate of this complication stands at 1.6%. The management of this complication hinges on either balloon dilation or valve replacement. This article discusses a case involving a 78-year-old man with symptomatic severe aortic valve stenosis. Following TAVR, the patient experienced asystole due to valve infolding, highlighting the need for heightened vigilance and refined intervention strategies in the management of TAVR complications.

Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is high risk compared to non-CTO PCI. Iatrogenic coronary artery hematoma formation is a common occurrence during CTO PCI, impairing true lumen visualization. We describe the use of a continuous mechanical suction (CMS) device in 2 applications in which it was used for successful subintimal hematoma decompression and distal vessel re-entry. Additionally, we briefly review CMS utilization within the published literature. CMS use during CTO may be a viable technique in future revascularization attempts.